GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (NAS:NVCR) » Definitions » Market Cap

NovoCure (NovoCure) Market Cap : $2,366.4 Mil (As of May. 19, 2024)


View and export this data going back to 2015. Start your Free Trial

What is NovoCure Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). NovoCure's share price for the quarter that ended in Mar. 2024 was $15.63. NovoCure's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 107.6 Mil. Therefore, NovoCure's market cap for the quarter that ended in Mar. 2024 was $1,681.9 Mil.

NovoCure's quarterly market cap declined from Sep. 2023 ($1,724.0 Mil) to Dec. 2023 ($1,598.6 Mil) but then increased from Dec. 2023 ($1,598.6 Mil) to Mar. 2024 ($1,681.9 Mil).

NovoCure's annual market cap declined from Dec. 2021 ($7,806.1 Mil) to Dec. 2022 ($7,705.3 Mil) and declined from Dec. 2022 ($7,705.3 Mil) to Dec. 2023 ($1,598.6 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. NovoCure's Enterprise Value for Today is $2,091.5 Mil.


NovoCure Market Cap Historical Data

The historical data trend for NovoCure's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Market Cap Chart

NovoCure Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,387.26 17,707.88 7,806.14 7,705.34 1,598.64

NovoCure Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,386.09 4,424.11 1,723.98 1,598.64 1,681.85

Competitive Comparison of NovoCure's Market Cap

For the Medical Devices subindustry, NovoCure's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovoCure's Market Cap Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Market Cap distribution charts can be found below:

* The bar in red indicates where NovoCure's Market Cap falls into.



NovoCure Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

NovoCure's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$14.93*107.076
=$1,598.6

NovoCure's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$15.63*107.604
=$1,681.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NovoCure  (NAS:NVCR) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


NovoCure Market Cap Related Terms

Thank you for viewing the detailed overview of NovoCure's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


NovoCure (NovoCure) Business Description

Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.
Executives
Pritesh Shah officer: Chief Commercial Officer C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Michal Nath Puri officer: Chief Human Resources Officer BUSINESS VILLAGE D4, PARK 6/PLATZ10, ROOT V8 6039
Wilhelmus Cm Groenhuysen officer: Chief Financial Officer C/O NAVTEQ CORPORATION, 222 MERCHANDISE MART STE 900, CHICAGO IL 60654
Ashley Cordova officer: Chief Financial Officer 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
Arye Barak Ben officer: General Counsel TOPAZ BUILDING, 4TH FLOOR, MATAM CENTER, PO BOX 15022, SH'AR HACARMEL, HAIFA L3 31905
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Kristin Stafford director 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE PA 19087
Frank X Leonard officer: President, CNS Cancers US 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
William Patrick Burke officer: Chief Human Resources Officer 195 COMMERCE WAY, PORTSMOUTH NH 03801
Uri Weinberg officer: Chief Innovation Officer NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Allyson J Ocean director 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE PA 19087
Asaf Danziger director, officer: Chief Executive Officer 5 NACHUM CHAT ST., TIRAT HACARMEL L3 5112302
Ely Benaim officer: Chief Medical Officer C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
William F Doyle director, 10 percent owner
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025